Baseline characteristics in the original and matched sub-cohort
| Original cohort (n=151) | Matched sub-cohort (n=76) | |||||||||||||
| STN-DBS | MED | P value* | STN-DBS | SD | MED | P value* | ||||||||
| n | M | SD | n | M | SD | n | M | n | M | SD | ||||
| Age | 67 | 61.3 | 8.5 | 84 | 65.8 | 10.4 | 0.003 | 38 | 62.0 | 8.9 | 38 | 62.5 | 11.5 | 0.743 |
| Disease duration | 67 | 10.8 | 4.9 | 84 | 7.5 | 5.0 | <.001 | 38 | 9.9 | 4.2 | 38 | 8.7 | 5.3 | 0.115 |
| Sex (female/male) (%) | 67 | 25/42 | (37.3/62.7) | 84 | 26/58 | (31/69) | 0.412 | 38 | 12/26 | (31.6/68.4) | 38 | 8/30 | (21.1/78.9) | 0.297 |
| NMSS total score | 67 | 60.6 | 36.0 | 83 | 46.0 | 25.3 | 0.01 | 38 | 54.2 | 34.5 | 38 | 46 | 22.1 | 0.436 |
| Cardiovascular | 67 | 1.4 | 2.3 | 84 | 1.0 | 1.9 | 0.549 | 38 | 0.8 | 1.3 | 38 | 1.3 | 2.3 | 0.489 |
| Sleep/fatigue | 67 | 14.7 | 10.1 | 84 | 9.2 | 8.6 | <.001 | 38 | 13.0 | 9.1 | 38 | 7.4 | 6.9 | 0.007 |
| Mood/ apathy | 67 | 6.5 | 11.2 | 84 | 6.7 | 8.4 | 0.215 | 38 | 6.3 | 12.1 | 38 | 7.4 | 8.3 | 0.129 |
| Perceptual problems/hallucinations | 67 | 1.2 | 3.1 | 84 | 1.1 | 2.3 | 0.574 | 38 | 1.1 | 3.3 | 38 | 1.0 | 2.3 | 0.621 |
| Attention/memory | 67 | 5.0 | 6.2 | 84 | 4.6 | 5.3 | 0.668 | 38 | 5.5 | 5.6 | 38 | 5.3 | 5.1 | 0.9 |
| Gastrointestinal | 67 | 5.8 | 7.3 | 84 | 4.6 | 5.3 | 0.615 | 38 | 4.4 | 5.5 | 38 | 4.9 | 5.7 | 0.75 |
| Urinary | 67 | 11.5 | 9.7 | 84 | 7.3 | 6.8 | 0.018 | 38 | 10.6 | 9.8 | 38 | 6.5 | 6.3 | 0.122 |
| Sexual function | 67 | 3.4 | 5.2 | 84 | 4.2 | 5.8 | 0.529 | 38 | 3.0 | 4.7 | 38 | 5 | 5.5 | 0.085 |
| Miscellaneous | 67 | 10.9 | 9.1 | 83 | 7.9 | 6.1 | 0.078 | 38 | 9.2 | 8.7 | 38 | 7.3 | 5.5 | 0.657 |
| PDQ-8 SI | 67 | 32.8 | 18.5 | 84 | 26.2 | 15.4 | 0.02 | 38 | 29.1 | 18.8 | 38 | 29.6 | 14.7 | 0.495 |
| SCOPA-motor examination | 67 | 11.6 | 5.2 | 84 | 10.1 | 4.6 | 0.077 | 38 | 10.8 | 5.2 | 38 | 12.2 | 4.4 | 0.147 |
| SCOPA-activities of daily living | 67 | 6.9 | 3.4 | 84 | 6.4 | 3.0 | 0.376 | 38 | 6.4 | 3.8 | 38 | 7.2 | 2.9 | 0.224 |
| SCOPA-motor complications | 67 | 4.8 | 3.1 | 84 | 3.1 | 1.7 | <0.001 | 38 | 3.6 | 3.0 | 38 | 3.4 | 2.0 | 0.929 |
| LEDD | 67 | 1199.1 | 587.5 | 84 | 778.1 | 407.1 | <0.001 | 38 | 1011.3 | 518.2 | 38 | 913 | 383.6 | 0.54 |
Demographic characteristics and outcome parameters at baseline in the original and matched cohorts. Significant results are highlighted in bold font.
*Mann-Whitney U test or t-test, when parametric test criteria were fulfilled.
LEDD, levodopa equivalent daily dose; MED, standard-of-care medical treatment; NMSS, Non-motor Symptom Scale; PDQ-8 SI, 8-item Parkinson’s Disease Questionnaire Summary Index; SCOPA, Scales for Outcomes in Parkinson’s disease; STN-DBS, subthalamic nucleus deep brain stimulation.